Rahmanian Masoud, Meybodi Hamidreza Aghaei, Larijani Bagher, Mohajeri-Tehrani Mohammad-Reza
EMRC (Endocrinology and Metabolism Research Institute), Shariati Hospital,Tehran university of medical science, North Karegar St, Tehran, Iran.
J Diabetes Metab Disord. 2013 Jan 8;12(1):3. doi: 10.1186/2251-6581-12-3.
"Invasive giant prolactinoma" is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms. Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. After 18 months, tumor size markedly reduced, associated with adrenal function and visual field improvement, but central hypogonadism and secondary hypothyroidism persisted.Previous studies showed normalization of thyrotropin secretion after treatment but it remained low in our patient even after 18 months follow up.
“侵袭性巨大泌乳素瘤”是一种大型泌乳素瘤（直径>4厘米），血清泌乳素水平>1000 ng/dL，并伴有与肿块相关的临床症状。在此，我们报告一例患有巨大泌乳素瘤的患者，该患者出现中枢性性腺功能减退、肾上腺和甲状腺功能受抑制、鞍上扩展、视野缺损以及高泌乳素水平。该患者接受了卡麦角林、左甲状腺素和泼尼松龙治疗。18个月后，肿瘤大小显著缩小，肾上腺功能和视野有所改善，但中枢性性腺功能减退和继发性甲状腺功能减退仍然存在。既往研究表明治疗后促甲状腺素分泌恢复正常，但在我们的患者中，即使经过18个月的随访，促甲状腺素水平仍较低。
